Peptides Explained

Eli Lilly is taking legal action against businesses selling products labeled retatrutide. What do the lawsuits actually establish—and what don't they? John Garrett separates pending legal allegations from court findings, reviews the human trial evidence for the investigational triple agonist, and explains why molecular identity, purity, and pharmaceutical equivalence are not interchangeable. We also examine FDA restrictions, consumer safety, and the implications for clinics, vendors, and independent educators. Educational only; not medical or legal advice. Retatrutide is not FDA-approved. Sources: NEJM DOI 10.1056/NEJMoa2301972; FDA unapproved GLP-1 drug concerns; ClinicalTrials.gov NCT05929066 and NCT05882045.

Can peptide biology protect the brain from vascular damage? John follows a question that started with Vesugen into the biology of vascular cognitive impairment—endothelial dysfunction, hypoperfusion, blood-brain-barrier injury, mitochondrial stress, inflammation and neuronal damage. The episode maps Cerebrolysin, SS-31/elamipretide, ARA-290/cibinetide, Semax, Vesugen and GLP-1 receptor agonists onto different points in that cascade, then asks the question that matters: what does the human evidence actually support? Cerebrolysin provides the biggest surprise, with randomized vascular-dementia trials—but still low-certainty evidence. Educational only; not medical advice.

Everyone keeps calling belly fat "visceral fat." That is not how anatomy works. In this crossover episode, John breaks down the difference between visceral and subcutaneous fat, why visceral adipose tissue matters metabolically, how it is actually measured, what waist circumference can and cannot tell you, and what the evidence says about GLP-1 therapies and tesamorelin.

Vesugen is only three amino acids long: lysine, glutamate, and aspartate — KED. Yet it is promoted as a vascular bioregulator that may support endothelial health and even "rejuvenate" aging blood vessels.

In this episode, John Garrett looks at what the endothelial research actually measured, the proposed gene-regulation mechanism, a small human blood-flow report, and the large gap between an interesting cell signal and a proven cardiovascular therapy.

No hype. No dismissal. Just the biology, the evidence, and what remains unknown.

INSTAGRAM CAPTION

Three amino acids.

K. E. D.

And somehow that became a claim about "rejuvenating" aging blood vessels.

Vesugen is one of the more interesting Khavinson bioregulator peptides because there is actual published endothelial-cell research behind the concept.

But there is a big difference between:

changing a cell marker

improving endothelial function

and preventing cardiovascular disease.

In the new episode of Peptides Explained, I break down the mechanism, the human signal, the evidence gaps, and the question that matters most:

Can Vesugen actually make aging blood vessels younger — or is the marketing way ahead of the science?

Educational only. Not medical advice.

#PeptidesExplained #Vesugen #KEDPeptide #Peptides #Longevity #VascularHealth #EndothelialHealth #CardiovascularHealth #HealthyAging #Biohacking #PeptideScience #MedicalScience

FLGR-242 is being called a smarter, longer-acting follistatin. John examines the advertised construct, the activin-sparing and 19-day half-life claims, the difference between pathway evidence and product evidence, and why transformation photos cannot establish pharmacology or safety.

Follistatin can bind myostatin—one of the body's major restraints on skeletal-muscle growth. Animal studies are dramatic, and small human gene-therapy studies have produced encouraging signals in serious muscle disease.

But is a vial labeled "Follistatin-344" equivalent to the therapy used in those trials?

John Garrett explains FST288, FST315, and FST344; the myostatin/activin pathway; the difference between gene therapy and recombinant protein; the evidence for muscle size versus function; and the key safety and product-identity questions.

Follistatin is not an FDA-approved muscle-building medication. Educational content only; not medical advice.

Explore the free Peptides Explained app: https://app.peptidesexplained.info

Glutathione gets called the "master antioxidant," and the underlying biology really is important. But does that mean oral supplements, liposomal products or glutathione IVs deliver the sweeping detox, energy, immune and anti-aging benefits often attached to them?

John breaks down glutathione biology, the GSH/GSSG cycle, oral human data, NAC, skin-related research and the gap between changing a biomarker and changing a meaningful health outcome. The episode also covers the 2026 FDA warning and recalls involving compounded injectable glutathione and elevated endotoxin levels.

The key question: where does established biology end and wellness marketing begin?

Educational only. Not medical advice.

For more information on Research Peptides go to PeptidesExplained.info/OfflinePeptides

Is taking smaller GLP-1 doses multiple times per week actually "microdosing"? Not necessarily.

This episode separates split dosing from true dose reduction and explains the pharmacokinetic logic using semaglutide, tirzepatide, and retatrutide. John breaks down half-life, peaks, troughs, total exposure, and why changing the schedule does not automatically mean using less drug.

We also examine the major evidence gap: once-weekly dosing has a strong clinical foundation for semaglutide and tirzepatide, while retatrutide remains investigational — and direct randomized evidence showing routine split dosing is superior is not established.

Educational only. No individualized dosing protocols are provided.

Download The Peptide App at ThePeptide.App/Explained

For more information on research peptides check out PeptidesExplained.info/OfflinePeptides

A peptide…in a pill?

Icotyde, or icotrokinra, is an FDA-approved oral peptide designed to block the IL-23 receptor in moderate-to-severe plaque psoriasis. In Phase 3 trials, it produced substantial skin clearance and outperformed an established oral comparator on several key endpoints.

But the biggest story may be the delivery platform itself. Peptides usually struggle to survive the digestive tract and reach circulation. Icotyde shows what can happen when medicinal chemistry, structural engineering and extreme receptor potency come together.

This episode breaks down what worked, what the safety data show, and what this does—and does not—mean for the future of oral peptides.

Educational only. Not medical advice.

If BPC-157, TB-500, KPV, MOTS-C and similar peptides are so interesting, why don't we have giant randomized human trials?

This episode looks at the less dramatic—and more important—answer: clinical trials require a sponsor, regulatory strategy, manufacturing package, defined indication, safety program, and a very large amount of money. For old, easily copied, poorly protected, or commercially fragmented compounds, the incentive to fund definitive trials may be weak.

John also explains why that does not excuse the evidence gap. "No Phase 3 trial" is not proof that a peptide works. It simply means confidence should remain limited until better evidence exists.

Educational only. Not medical advice.

Download The Peptide App @ ThePeptide.App/Explained

For more info on research peptides visit PeptidesExplained.info/OfflinePeptides

John Garrett shares his N=1 experience with the so-called "Trinity Stack"—established TRT, retatrutide, and tesamorelin—combined with resistance training, Zone 2 cardio, high protein intake, creatine, sauna, and cold plunging.

The transformation was dramatic. But what likely came from appetite control? What helped preserve muscle? What might the GH/IGF-1 axis have added? And how much credit belongs to the boring fundamentals?

This is a candid personal testimony and accessible science breakdown—not a deep dive, a dosing guide, or a warning lecture. John also explains what happened during an eight-week break and why he recently restarted with a goal of reaching 10% body fat.

Educational only. Retatrutide remains investigational and is not FDA-approved.

SNAP-8 is a synthetic cosmetic octapeptide marketed for expression lines and frequently called "Botox in a bottle." John Garrett, RN, breaks down the SNAP-25 and SNARE-complex mechanism, the difference between topical SNAP-8 and injected botulinum toxin, the skin-penetration problem, the Argireline evidence, a small 2024 microneedle combination study, safety, and the limits of the current human data.

The mechanism is plausible. The evidence is not strong enough to call it a needle-free Botox equivalent.

Educational content only; not medical advice.

Visit peptidesexplained.info for more info and resources

For more info on research peptides check out PeptidesExplained.info/OfflinePeptides or email John at john@peptidesexplained.info

What exactly is GLP-1 microdosing?

Depending on who you ask, it can mean remaining on the starter dose, taking a fraction of that dose, spacing injections farther apart, stepping down after weight loss, or using a tiny amount for food noise and longevity.

Those are not the same strategy.

John Garrett breaks down the new low-dose semaglutide and tirzepatide data, FDA-approved dose structures, weight-regain research, maintenance questions, side effects, and the major gap between individualized clinical titration and social-media "microdosing" protocols.

Educational content only. Not medical advice.

Can a peptide reverse age-related immune decline?

Thymalin and Thymogen are often discussed together, but one is a complex calf-thymus extract and the other is the defined dipeptide Glu-Trp. John Garrett explains thymic involution, T-cell biology, proposed mechanisms, the Russian clinical history, limitations of the human evidence, safety, and U.S. regulatory status.

The science is interesting. The "immune rejuvenation" and life-extension claims remain unproven.

Educational only. Not medical advice.

Check out The Peptide App here: thepeptide.app/explained

What is Pinealon, and does this three-amino-acid peptide really protect the aging brain?

Pinealon—also called EDR or Glu-Asp-Arg—is a synthetic tripeptide associated with the Khavinson bioregulator research program. It is discussed for memory, neuroprotection, oxidative stress, brain aging, and even Alzheimer's disease, but the evidence is much more complicated than the marketing language suggests.

John Garrett, examines Pinealon's proposed mechanism, cell and animal research, a newer induced-neuron study, and the PubMed-indexed human reports that are often overlooked. The episode also explains why Pinealon is different from Epitalon, where the human evidence is weak, what remains unknown about brain exposure and long-term safety, and why a plausible mechanism is not the same thing as an established cognitive therapy.

Educational content only. Not medical advice.

What are Khavinson peptide bioregulators, and what do they actually do?

John Garrett examines the Russian research tradition behind organ-derived peptide complexes and synthetic ultrashort peptides. This episode explains the proposed gene-expression mechanism, the claim of tissue specificity, common examples such as Thymalin and Epitalon, the limitations of the human evidence, oral absorption questions, product-quality concerns, safety, and U.S. regulatory status.

The science is more interesting than a simple dismissal—but less proven than organ-rejuvenation marketing suggests.

This episode is educational and is not medical advice.

Does a weight-loss plateau mean your GLP-1 receptors have become desensitized? John separates cellular receptor biology from whole-body weight regulation and compares semaglutide, tirzepatide, and investigational retatrutide. We examine appetite suppression, food noise, gastric-emptying tachyphylaxis, metabolic adaptation, switching therapies, and what the clinical evidence can—and cannot—tell us.

A plateau is real. "Receptor burnout" is a much bigger claim.

Educational only; not medical advice.

Visit Peptide-Solutions.info for more info

Check out App.PeptidesExplained.info

Should you be using peptides?

The honest answer is that not everyone should. Peptides are not a nutritional requirement, a shortcut to better health, or something you need simply because they are trending.

But some people do have a defined problem—such as obesity, metabolic disease, an injury, loss of function, a diagnosed hormone-related condition, or another health issue—for which a peptide-based medication or investigational compound may be relevant.

In this episode, John Garrett, explains how to decide whether a peptide belongs in the conversation. You will learn how to start with the problem rather than the product, compare FDA-approved, off-label, compounded, experimental, and research-use categories, evaluate human versus animal versus anecdotal evidence, identify better-established alternatives, and build a plan for monitoring and stopping.

This episode also points viewers to "The 11 Peptides I Find Most Compelling" and the individual Peptides Explained deep dives for compound-specific education.

This content is educational only and is not medical advice. Speak with a qualified healthcare professional before starting, stopping, or changing any therapy.

ARA-290, also called cibinetide, is an investigational 11-amino-acid peptide designed from erythropoietin biology to activate tissue-protective signaling without stimulating red-blood-cell production.

In this episode, John Garrett, RN, breaks down the innate repair receptor, why ARA-290 has been studied in small-fiber neuropathy, what randomized human trials in sarcoidosis and type 2 diabetes actually found, and why objective nerve-fiber signals are interesting—but not the same thing as an approved therapy.

You'll learn:

• What ARA-290/cibinetide is

• How it differs from full-length erythropoietin

• What the innate repair receptor is

• Why researchers studied corneal nerve fibers

• What the 22-patient pilot trial showed

• What the 64-patient phase 2b trial showed

• Why pain and nerve-fiber endpoints did not tell exactly the same story

• What is known—and not known—about safety

• Why online ARA-290 products should not be assumed equivalent to trial material

Explore the Peptides Explained app: app.peptidesexplained.info

Learn more through Peptide Solutions: peptide-solutions.info

Educational content only. ARA-290 is investigational and is not an FDA-approved treatment for neuropathy or any other clinical indication.

Check out Peptide.Solutions.info/Pathways and submit a request to see what companies I have partnered with to get products.

Lipo-C injections are often marketed for fat burning, energy, liver support, or breaking a weight-loss plateau. But "Lipo-C" is not one standardized formula—and real metabolic biology is not the same thing as proven fat loss.

In this episode, John Garrett, RN, breaks down the ingredients commonly found in Lipo-C blends, including L-carnitine, choline, methionine, inositol, and B vitamins. We examine what each ingredient actually does, what human studies of L-carnitine suggest, why that evidence cannot automatically be applied to a compounded injection, and the questions to ask before paying for one.

You'll learn:

• Why two products called Lipo-C may be completely different

• How carnitine participates in mitochondrial fatty-acid oxidation

• What "lipotropic" does—and does not—mean

• Whether Lipo-C is FDA approved

• What people report versus what trials establish

• Risks, limitations, and when provider involvement matters

Explore the Peptides Explained app: app.peptidesexplained.info

Learn more through Peptide Solutions: peptide-solutions.info

Educational content only. This is not medical advice or a recommendation to use an injectable product.

FOXO4-DRI has been called a "zombie-cell killer," a senolytic peptide, and even a possible anti-aging breakthrough. The mechanism is fascinating—but the claims have moved much faster than the human evidence.

In this episode, John explains what senescent cells are, why they are not automatically harmful, and how FOXO4 and p53 help regulate cell survival and cell death. He then breaks down the D-retro-inverso design of FOXO4-DRI, the proposed mechanism, and what the original 2017 research actually found in cultured human cells and mice.

The episode also examines what has happened since that first study, why removing senescent cells may produce different effects in different tissues, and what the cancer, tissue-repair, regulatory, and long-term safety questions really look like.

The bottom line: FOXO4-DRI is a scientifically credible experimental senolytic with compelling preclinical biology—but it has not been proven to reverse aging or provide clinical benefit in humans.

Explore the Peptides Explained App:

https://app.peptidesexplained.info

Peptide Solutions:

If you are interested in checking out Compounded or Research Peptide Sources visit Peptide Solutions. https://peptide-solutions.info

This episode is educational and is not individualized medical advice. FOXO4-DRI is experimental and is not an FDA-approved medication.

ATX-304 is often called "exercise in a pill," but it is more accurate to describe it as an investigational oral small molecule that activates AMPK and alters mitochondrial energy demand. John explains the mechanism, the preclinical metabolic findings, the early human signal in type 2 diabetes, the current obesity-development strategy, and the major gaps that remain before anyone can claim it reproduces the health effects of exercise.

2. Offline Peptides

I am an affiliate with each of these companies. If you use my link I may earn a commission at no extra cost to you.

All information on this podcast is for educational and not meant as medical advice.

Thymosin alpha 1—also called Tα1 or thymalfasin—is frequently described online as an "immune-boosting peptide." But that phrase oversimplifies a complicated biological system.

In this episode of Peptides Explained, John Garrett breaks down how thymosin alpha 1 may influence dendritic cells, Toll-like receptor signaling, T-cell maturation, natural-killer-cell activity, cytokines, and immune regulation. The episode also reviews where it has been studied, including chronic viral hepatitis, vaccine response, oncology-support settings, severe infection, pancreatitis, and sepsis.

The evidence is not uniformly positive. Earlier sepsis trials and pooled analyses suggested benefit, but a large multicenter phase 3 trial involving more than 1,100 adults found no reduction in 28-day mortality. That contrast illustrates why biological mechanisms and small clinical studies must be separated from confirmed patient outcomes.

The episode also covers:

• What thymosin alpha 1 is

• Why "immune modulator" is more accurate than "immune booster"

• Innate versus adaptive immunity

• Human clinical evidence versus cell and animal research

• International approval versus U.S. FDA status

• FDA concerns involving compounded thymosin alpha 1

• Potential risks, product-quality concerns, and major unknowns

• A responsible decision framework for evaluating immune-peptide claims

This content is for education and discussion only and is not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any therapy.

Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use the link below, I may earn a commission at no additional cost to you.

PeptidesExplained.info/OfflinePeptides

#ThymosinAlpha1 #Thymalfasin #PeptidesExplained #ImmuneSystem #Immunology #PeptideScience #TCells #Longevity #Peptides #MedicalEducation

The State of Peptides 2026 | Clinician Webinar

The peptide landscape is changing rapidly. New research is emerging, regulatory decisions continue to shape clinical practice, and healthcare providers are being asked more questions than ever before.

Join Peptide Solutions for a live clinician-focused webinar covering the current state of peptides in 2026. This educational session is designed for physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other healthcare professionals interested in understanding the latest developments.

• The current peptide and GLP-1 landscape • Recent FDA and PCAC regulatory updates • The most commonly discussed therapeutic peptides • Current evidence and clinical data • Safety, quality, and sourcing considerations • What providers should expect moving forward

📅 August 13, 2026 🕖 7:00 PM Central Time

Register: https://peptide-solutions.info

This webinar is intended for educational purposes only. Peptide Solutions does not diagnose, treat, prescribe, compound, or dispense medications. Prescription therapies require evaluation and oversight by a licensed healthcare provider. Discussions of research peptides are for educational purposes only and should not be interpreted as recommendations for human use.

After researching peptide science week after week—and using some compounds personally—I'm answering one of the most common questions I receive: Which peptides do I find the most useful and compelling?

This is not a universal ranking or a recommendation to use all 11. Tirzepatide, retatrutide, tesamorelin, ipamorelin, BPC-157, TB-500, GHK-Cu, KPV, PT-141, MOTS-c, and SS-31 occupy very different evidence and regulatory categories. Some are FDA-approved prescription drugs. Some have encouraging human data. Others remain experimental and are supported mainly by animal, cell, mechanistic, or anecdotal evidence.

In this episode, we examine the problem each peptide is intended to solve, how it works, what the human evidence shows, where the evidence is weak, known risks, regulatory status, and why each compound made my personal list.

This episode is for education and discussion only. It is not medical advice. Always involve a qualified healthcare professional before starting, stopping, or changing a therapy.

Peptides Explained is an affiliate partner with OfflinePeptides.com.

Visit PeptidesExplained.info/OfflinePeptides.

For Peptides through a compounding pharmacy or a telehealth option

Visit Peptide-Solutions.info and submit a request for more information.

GLP-1 medications changed obesity treatment, but appetite regulation involves more than one hormonal signal. Cagrilintide is a long-acting analogue of amylin, a pancreatic peptide released alongside insulin that helps regulate satiety, gastric emptying, and post-meal glucagon signaling.

In this episode of Peptides Explained, John Garrett breaks down what cagrilintide is, how it differs from GLP-1 receptor agonists, what standalone phase 2 data show, and what the phase 3 CagriSema trials tell us about combining cagrilintide with semaglutide.

We also examine the REDEFINE 4 comparison with tirzepatide, common gastrointestinal adverse effects, unresolved questions about long-term outcomes and lean mass, and why online research products should not be treated as equivalent to the pharmaceutical trial material.

Cagrilintide remains investigational and is not currently an FDA-approved treatment. This content is educational and is not medical advice.

Peptides Explained is an affiliate partner with Offline Peptides. Research-use products are not approved medications and are not intended for human use.

Visit: PeptidesExplained.info/OfflinePeptides

For information on Compounded Peptides through Premier Pharmacy visit Peptide Solutions and submit a request for more information

Visit: Peptide-Solutions.info and submit a request for more information

Send a two- to three-minute N=1 video to john@peptidesexplained.info.

AOD-9604 is often marketed as the "fat-burning fragment" of human growth hormone. But what does it actually do, and did it work in human obesity trials?

In this episode of Peptides Explained, John Garrett, RN, breaks down:

• What AOD-9604 is and how it differs from full-length HGH

• Lipolysis, lipogenesis, and beta-3 adrenergic signaling

• Why animal studies looked promising

• What the early human trials showed

• Why the obesity-development program was discontinued

• Whether AOD-9604 raises IGF-1

• Regulatory status, risks, unknowns, and anti-doping concerns

• A responsible framework for evaluating experimental fat-loss peptides

The central takeaway: AOD-9604 has a plausible preclinical mechanism, but the available human evidence does not establish dependable, clinically meaningful fat loss.

This episode is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any therapy.

This episode is brought to you by Offline Peptides. If you are interested in Research Peptides Learn more at

PeptidesExplained.info/OfflinePeptides.

For more information about Peptide Solutions, visit Peptide-Solutions.info.

Send your 2–3 minute N=1 video to john@peptidesexplained.info.

SLU-PP-332 is being promoted as an "exercise mimetic" that may increase fat oxidation, endurance, and energy expenditure. But it is not actually a peptide, it is not FDA-approved, and the most compelling evidence comes from cell and mouse research—not human clinical trials.

In this episode, John Garrett, RN, explains estrogen-related receptors, mitochondrial energy metabolism, the published preclinical findings, the oral-bioavailability problem, potential risks, regulatory status, and the difference between mimicking selected exercise pathways and replacing physical exercise.

This content is for education and discussion only and is not medical advice. SLU-PP-332 is an experimental research compound with no established human therapeutic use.

Learn more: PeptidesExplained.info

Peptide Solutions: Peptide-Solutions.info

Offline Peptides: PeptidesExplained.info/OfflinePeptides

Affiliate disclosure: Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use my link, I may earn a commission at no additional cost to you.

Send 2–3 minute N=1 videos to john@peptidesexplained.info.

Why are Americans living longer than ever before while spending more years battling chronic disease?

In this episode of Peptides Explained, we explore one of the biggest questions in longevity medicine: the difference between lifespan and healthspan.

You'll learn why muscle loss, metabolic dysfunction, chronic inflammation, mitochondrial decline, immune aging, and cognitive changes are major drivers of aging—and where peptide research may fit into each of these biological systems.

We discuss several categories of peptides currently being investigated, including:

• Growth Hormone Secretagogues (Tesamorelin, Ipamorelin, Sermorelin, CJC-1295) • GLP-1 and Metabolic Peptides (Semaglutide, Tirzepatide, Retatrutide) • Anti-Inflammatory Peptides (KPV, Thymosin Alpha-1, BPC-157) • Regenerative Peptides (BPC-157, TB-500, GHK-Cu) • Nootropic Peptides (Semax, Selank, Dihexa) • Mitochondrial Peptides (MOTS-c, SS-31, Epitalon)

This episode discusses current science, emerging research, and where evidence is strong—and where it is still evolving.

This podcast is for educational purposes only and is not medical advice.

Sponsored by Peptide Solutions

Learn more: https://peptide-solutions.info

Research Peptides (Affiliate):

PeptidesExplained.info/OfflinePeptides

Affiliate Disclosure: Peptides Explained is an affiliate partner with Offline Peptides.

#Peptides #HealthyAging #Longevity #GLP1 #Retatrutide #Semaglutide #BPC157 #MOTSc #Healthspan #PeptidesExplained

NAD+ is one of the most talked-about molecules in longevity and wellness. It is marketed for energy, mitochondrial support, cellular repair, brain fog, recovery, and anti-aging.

But what happens when we bring cancer biology into the conversation?

In this episode of Peptides Explained, we break down the relationship between NAD+ and cancer in clear, responsible language. NAD+ is essential for normal cellular function, DNA repair, mitochondrial energy production, redox balance, and immune signaling. But cancer cells may also rely on NAD+ metabolism to support growth, survival, DNA repair, oxidative stress control, and possible treatment resistance.

This episode covers NAD+, NADH, NR, NMN, niacinamide, IV NAD+, NAMPT, PARP enzymes, DNA repair, cancer therapy, human evidence, preclinical evidence, and why active cancer or recent cancer changes the risk discussion.

This is not a hype episode and not a fear episode. The real answer is context.

NAD+ biology is real. The cancer concern is biologically plausible. The human evidence is incomplete.

This podcast is for informational purposes only and is not medical advice. Always consult a licensed healthcare professional before considering any therapy, supplement, peptide, injection, or infusion.

Peptides Explained is powered by Peptide Solutions.

Learn more: peptide-solutions.info

Affiliate disclosure: Peptides Explained is an affiliate partner with Offline Peptides . If you use my link, I may earn a commission at no additional cost to you.

PeptidesExplained.info/OfflinePeptides

#NAD #NADPlus #NMN #NR #CancerBiology #LongevityScience #Mitochondria #DNARepair #NAMPT #PARP #PeptidesExplained #PeptideScience

Description

Can a tiny peptide discovered nearly 50 years ago hold the key to better sleep?

In this episode of Peptides Explained, we explore Delta Sleep-Inducing Peptide (DSIP)—one of the most mysterious compounds in peptide research. Unlike many peptides discussed today, DSIP has no confirmed receptor, conflicting clinical data, and decades of unanswered questions.

In this episode you'll learn:

✔️ What DSIP is ✔️ How sleep is biologically regulated ✔️ The fascinating history of DSIP's discovery in the 1970s ✔️ Proposed mechanisms involving GABA, serotonin, dopamine, and the HPA axis ✔️ Human and animal research findings ✔️ Potential side effects and safety considerations ✔️ Why DSIP is not FDA approved and why no major medical organization recommends it for insomnia or other sleep disorders

This podcast is intended for educational purposes only and is not medical advice.

🌐 Peptide Solutions https://peptide-solutions.info

🧬 Research Peptides (Affiliate Partner) PeptidesExplained.info/OfflinePeptides

If you use my affiliate link, I may receive a commission at no additional cost to you.

📧 N=1: Your Real-World Results

Have you researched DSIP?

Send a 2–3 minute video describing your experience to:

john@peptidesexplained.info

You may be featured in a future episode.

#DSIP #SleepPeptide #Peptides #SleepScience #Insomnia #Longevity #PeptidesExplained #SleepResearch #Neuroscience #Biohacking

5-Amino-1MQ is often talked about in peptide circles, but it is not actually a peptide. It is a small-molecule NNMT inhibitor being studied for its potential role in nicotinamide metabolism, NAD⁺ biology, methylation, fat-cell function, insulin sensitivity, and liver metabolism.

In this episode, John Garrett breaks down the proposed mechanism behind 5-Amino-1MQ, why people are discussing it for fat loss and body composition, and what the current research actually shows.

The data is interesting, especially in preclinical studies involving adipocytes, diet-induced obese mice, glucose tolerance, insulin sensitivity, and fatty liver markers. But the human clinical evidence is still limited, and 5-Amino-1MQ is not FDA-approved for fat loss, obesity, metabolic disease, longevity, or body composition.

This episode takes a balanced look at the science, the grey-market reality, and how to think about emerging metabolic compounds responsibly.

This podcast is for informational purposes only and is not medical advice. Always consult a licensed healthcare professional before considering any therapy.

Peptides Explained is powered by Peptide Solutions.

Peptides Explained is also an affiliate partner with Offline Peptides. If you use my link, I may earn a commission at no additional cost to you.

Offline Peptides affiliate link: https://offlinepeptides.com/ref/JohnGarrett/

Podcast website: https://peptidesexplained.info

Peptide Solutions: https://peptide-solutions.info

BPC-157 & TB-500 for Dogs: Healing, Recovery & the Current Science

Welcome to Episode 1 of the Peptides Explained Veterinary Series.

In this episode, we examine two of the most talked-about peptides in regenerative veterinary medicine—BPC-157 and TB-500.

We'll discuss what researchers currently know about these experimental peptides, why they're generating interest among veterinarians and dog owners, how they may influence tendon, ligament, muscle, and connective tissue repair, and where the evidence remains limited.

Whether you own an active family pet, a hunting dog, an agility competitor, or a working K9, this episode provides a balanced look at the science while separating evidence from online speculation.

Educational only. BPC-157 and TB-500 are experimental compounds and are not FDA-approved veterinary medications.

Learn more at https://peptide-solutions.info

Peptides Explained is an affiliate partner with Offline Peptides. If you use my link, I may earn a commission at no additional cost to you.

https://offlinepeptides.com/ref/JohnGarrett/

Have a real-world experience using peptides with your dog? Send a 2–3 minute horizontal video to john@peptidesexplained.info for a chance to be featured in our "N=1: Your Real-World Results" segment.

I asked ChatGPT a simple question... and the answer surprised me.

For Research Grade Peptides, check out Offline Peptides

🌐 ⁠OfflinePeptides.com/Ref/JohnGarrett⁠

If ChatGPT were a 47-year-old peptide researcher who needed to lose 40 pounds, had a nagging knee injury, wanted to preserve muscle, improve energy, and had an unlimited budget, what peptide stack would it choose?

Instead of recommending every popular peptide on the market, it built a surprisingly logical plan focused on solving the biggest problems first.

In this episode of Peptides Explained, we break down the science and reasoning behind each selection:

We also discuss why several well-known peptides didn't make the list, why ChatGPT preferred individual peptides over a Glow Stack, and how prioritizing your biggest health challenge may be more important than simply taking more compounds.

This episode is an educational thought experiment—not medical advice—and is designed to spark discussion about peptide science, mechanisms, and evidence.

Powered by Peptide Solutions

Looking for peptide education, research resources, or provider-guided peptide options?

🌐 https://peptide-solutions.info

For Research Grade Peptides, check out Offline Peptides

🌐 OfflinePeptides.com/Ref/JohnGarrett

Affiliate Disclosure: Peptides Explained is an affiliate partner with OfflinePeptides.com. If you choose to use my affiliate link, I may earn a commission at no additional cost to you.

Can a peptide actually slow the aging process?

In this episode of Peptides Explained, we take a deep dive into Epitalon—one of the most talked-about peptides in longevity medicine.

You'll learn:

What Epitalon is and where it came from

How telomeres and telomerase work

Why the pineal gland may play a role in aging

What the human and animal research actually shows

Why activating telomerase is both exciting and scientifically complex

The current FDA and regulatory status of Epitalon

The difference between promising mechanisms and proven clinical outcomes

Rather than relying on hype, we examine the available evidence and discuss what researchers know—and just as importantly, what they still don't know.

New Segment – N=1: Your Real-World Results

Have you used Epitalon or another peptide we've covered on the show?

I'd love to feature your experience in a future episode.

Record a 2–3 minute video sharing: • Which peptide you used • Why you decided to try it • Your results—positive, negative, or somewhere in between • Anything you learned along the way

Email your video to:

john@peptidesexplained.info

Your experience may be featured in an upcoming N=1: Your Real-World Results segment.

This podcast is for educational purposes only and is not medical advice.

SS-31 (Elamipretide) may be one of the most fascinating peptides ever developed.

Unlike most peptides that work by activating receptors on the surface of cells, SS-31 targets the mitochondria—the cellular power plants responsible for producing energy.

In this episode of Peptides Explained, we break down:

✅ What mitochondria actually do ✅ The role of cardiolipin in cellular energy production ✅ How SS-31 works biologically ✅ Why SS-31 received FDA Accelerated Approval in 2025 ✅ What Barth Syndrome is ✅ The latest human clinical data ✅ How SS-31 compares with MOTS-c ✅ Whether repairing mitochondria before metabolic optimization makes biological sense

We'll separate proven science from speculation and discuss what remains investigational.

This podcast is for informational purposes only and is not medical advice.

Support the Show

Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use my link, I may earn a commission at no additional cost to you.

https://offlinepeptides.com/ref/JohnGarrett/

For peptide education, provider resources, and information about compounded peptide options through licensed providers:

https://peptide-solutions.info

#PeptidesExplained #SS31 #Elamipretide #Forzinity #BarthSyndrome #Mitochondria #Longevity #MOTSc #Peptides

Most peptide users understand what peptide they want to use, but many struggle with the math behind vial size, reconstitution, concentration, units, volume, and medication calculations.

In this episode of Peptides Explained, we break down the fundamentals of peptide math in plain English. You'll learn the difference between total vial contents and dose, what reconstitution actually means, why concentration matters, how syringe units can create confusion, and the medication calculation formula used throughout healthcare.

Whether you're interested in GLP-1 medications, growth hormone secretagogues, BPC-157, TB-500, Tesamorelin, or other peptides, these mathematical principles apply across the board.

Topics Covered: • Vial Size vs. Dose • Reconstitution Explained • Concentration Made Simple • Units vs. Volume • The D ÷ H × V Medication Calculation Formula • Common Mistakes Peptide Users Make

This podcast is for informational and educational purposes only and is not medical advice.

Support the Show:

Visit Peptide Solutions: https://peptide-solutions.info

Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use my link, I may earn a commission at no additional cost to you.

https://offlinepeptides.com/ref/JohnGarrett/

What do tanning peptides have to do with sexual medicine?

More than you might think.

In this episode of Peptides Explained, we explore the fascinating science behind Melanotan I, Melanotan II, and PT-141 (Bremelanotide). What began as research into skin pigmentation and UV protection unexpectedly led to the development of an FDA-approved medication for hypoactive sexual desire disorder.

You'll learn:

• How the melanocortin system works • The role of alpha-MSH in pigmentation and physiology • The differences between Melanotan I and Melanotan II • Why Melanotan II became known for effects beyond tanning • How PT-141 was developed from Melanotan II research • The clinical data behind pigmentation and sexual function • Potential side effects and safety considerations • The current regulatory status of these compounds

Whether you're interested in peptide science, dermatology, sexual health, or drug development, this episode highlights one of the most unexpected stories in modern peptide research.

This podcast is for informational purposes only and is not medical advice.

Learn more at: 📍 Peptide-Solutions.info

Research Peptide Affiliate Partner: 📍 https://offlinepeptides.com/ref/JohnGarrett/

Affiliate Disclosure: Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use my link, I may earn a commission at no additional cost to you.

#PeptidesExplained #Melanotan #Melanotan2 #Melanotan1 #PT141 #Bremelanotide #PeptideTherapy #Longevity #HealthPodcast #MedicalScience

The founder of Offline Peptides joins Peptides Explained for a candid discussion about grey market peptides, quality control, regulation, and the future of the peptide industry.

What are grey market peptides, and why have they become one of the fastest-growing topics in health, wellness, longevity, and performance?

In this episode of Peptides Explained, host John Garrett sits down with Matthew Pacheco, founder of Offline Peptides, for an in-depth conversation about the current peptide landscape, quality control, consumer education, and the realities of the peptide industry.

Together, they discuss why peptides have exploded in popularity, what consumers should know about third-party testing and Certificates of Analysis (COAs), the challenges facing the industry, and how the regulatory environment may shape the future of peptide access.

This is not a sales pitch. It's an honest discussion about one of the most talked-about areas in modern health and wellness.

TOPICS COVERED

• What "grey market peptides" actually means • Why peptides have become so popular • Quality control and third-party testing • Understanding COAs and lab testing • Common misconceptions about peptides • Regulatory and FDA considerations • Consumer safety and education • The future of peptide research • The role of transparency in the peptide industry

GUEST

Matthew Pacheco Founder, Offline Peptides

PEPTIDE RESOURCES

Peptides Explained Podcast Website https://peptidesexplained.com

Peptide Solutions https://peptide-solutions.info

Peptide Solutions was created to help connect listeners with peptide education and peptide access pathways through trusted partners.

OPTION 1: RESEARCH PEPTIDES

Offline Peptides https://offlinepeptides.com/ref/JohnGarrett/

OPTION 2: LICENSED PROVIDER & COMPOUNDED PEPTIDES

Premier Pharmacy

For clinicians interested in prescribing peptides in their practice, or individuals interested in speaking with a licensed healthcare provider regarding peptide therapies, visit:

https://peptide-solutions.info

AFFILIATE DISCLOSURE

Peptides Explained is an affiliate partner with Offline Peptides. If you use the affiliate link above, I may earn a commission at no additional cost to you.

ABOUT PEPTIDES EXPLAINED

Peptides Explained is a podcast dedicated to helping listeners understand peptide science, mechanisms, clinical research, and real-world applications through evidence-based discussions and expert interviews.

DISCLAIMER

This podcast is for informational and educational purposes only and is not medical advice. Nothing discussed in this episode should be interpreted as medical, legal, or regulatory guidance. Always consult a qualified healthcare professional regarding your individual health needs.

#PeptidesExplained #OfflinePeptides #PeptideSolutions #Peptides #GLP1 #Retatrutide #Tirzepatide #Semaglutide #Longevity #Healthcare #MedicalEducation #FunctionalMedicine #WeightLoss #PeptideResearch

In this episode of Peptides Explained, we take a deep dive into KPV, a three-amino-acid peptide derived from alpha-melanocyte stimulating hormone (alpha-MSH) that has generated growing interest for its potential anti-inflammatory effects.

We explore the biology behind KPV, how it may influence inflammatory pathways such as NF-kB, and why researchers have studied it in models of ulcerative colitis, Crohn's disease, inflammatory bowel disease (IBD), and intestinal barrier dysfunction.

You'll learn:

• What KPV is and where it comes from • How KPV may reduce inflammatory signaling • The role of PepT1 transporters in the gut • What animal and laboratory studies have shown • The limitations of current human data • Why KPV has become popular in gut health discussions

We also examine the growing interest in the KLOW Blend, a combination of:

• KPV • BPC-157 • TB-500 • GHK-Cu

and discuss the scientific rationale behind combining these peptides to target inflammation, tissue protection, cellular migration, and regeneration.

As always, we separate biological mechanisms from marketing claims and review what the evidence actually shows.

Peptide Solutions is owned and operated by host John Garrett and helps educate both patients and healthcare professionals about peptide science and peptide therapy pathways.

Learn more at:

Peptide-Solutions.info

Peptides Explained is an affiliate partner with OfflinePeptides.com.

If you use the link below, I may earn a commission at no additional cost to you:

https://offlinepeptides.com/ref/JohnGarrett/

Healthcare providers interested in prescribing compounded peptides and individuals interested in telehealth consultation options can learn more through Peptide Solutions.

Visit:

Peptide-Solutions.info

Disclaimer: This podcast is for educational and informational purposes only and is not medical advice. KPV and the KLOW Blend are not FDA-approved therapies, and much of the research discussed comes from laboratory and animal studies. Always consult a licensed healthcare professional regarding medical decisions.

Powered By Peptide SolutionsResearch Peptide Affiliate DisclosureCompounded Peptide Information

In this episode of Peptides Explained, we take a deep dive into two of the most talked-about Russian research peptides: Selank and Semax.

We'll explore where these peptides came from, how they work in the brain, and why researchers have studied them for anxiety, stress resilience, cognitive performance, neuroprotection, and stroke recovery. You'll learn about key mechanisms involving GABA, dopamine, serotonin, BDNF, and neuroplasticity while separating scientific evidence from internet hype.

We also review the available clinical data, discuss regulatory status in the United States, and explain what is known—and still unknown—about the safety and effectiveness of these compounds.

Whether you're a clinician, researcher, peptide enthusiast, or simply curious about emerging neuroscience, this episode provides a balanced, evidence-based look at Selank and Semax.

Topics Covered: • What are Selank and Semax? • Russian peptide research history • Anxiety and stress-response signaling • BDNF and neuroplasticity • Cognitive enhancement claims • Stroke recovery research • Safety considerations and limitations • Current regulatory status

Support the Podcast

Peptides Explained is powered by Peptide Solutions, owned and operated by John Garrett.

For educational information about peptides and available options:

Peptide Solutions: https://peptide-solutions.info

For those interested in research-use peptides:

https://offlinepeptides.com/ref/JohnGarrett/

Affiliate Disclosure: Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use the affiliate link above, I may earn a commission at no additional cost to you.

This podcast is for informational and educational purposes only and does not constitute medical advice.

In this special episode of Peptides Explained, we're focusing on a topic that affects millions of women but often isn't discussed openly enough: menopause, hormonal signaling, libido, body composition, and the emerging role of peptides.

Why does weight gain seem different during menopause? What causes the sudden changes in energy, sleep, skin, hair, and sexual desire? And where do peptides like Kisspeptin, PT-141 (Bremelanotide), Tesamorelin, GHK-Cu, BPC-157, and GLP-1 medications fit into the conversation?

Join host John Garrett, RN, as he breaks down the science behind female hormone signaling in clear, understandable language. We'll explore the biology of menopause, the neurochemistry of desire, the "collagen cliff," metabolic changes, and the latest research on peptides being studied for women's health and aging.

This episode covers: • Menopause and metabolic changes • GLP-1 medications and weight management • Kisspeptin and reproductive hormone signaling • PT-141 and female sexual desire • Tesamorelin and growth hormone pathways • GHK-Cu and collagen production • BPC-157 and recovery science • Oxytocin and emotional connection • What is evidence-based vs. what remains experimental

Whether you're navigating perimenopause, menopause, or simply interested in understanding how peptide science intersects with women's health, this episode delivers a balanced, evidence-based look at one of the most important conversations in modern medicine.

Learn more: www.peptide-solutions.info

Podcast website: www.peptidesexplained.info

Support the podcast and learn more about peptide research: offlinepeptides.com/ref/JohnGarrett

Affiliate Disclosure: Peptides Explained is an affiliate partner with Offline Peptides. If you use my affiliate link, I may earn a commission at no additional cost to you.

Follow Peptides Explained: • Instagram: @PeptidesExplained • Facebook: Peptides Explained • LinkedIn: Peptides Explained • Patreon: Peptides Explained • Skool: Peptides Explained Community

If you enjoy the show, please follow, subscribe, leave a review, and share this episode with someone who would benefit from understanding the science behind menopause, hormones, and peptide therapy.

Peptides Explained is powered by Peptide Solutions, founded and operated by John Garrett, RN, providing education on peptide science and helping connect patients and clinicians with peptide-related resources.

This podcast is for informational purposes only and is not medical advice.

GLP-1 medications may affect far more than appetite and weight loss.

In this episode, we explore the growing evidence surrounding semaglutide, tirzepatide, and retatrutide and their potential effects on mood, anxiety, dopamine signaling, motivation, and compulsive behavior.

We discuss both the research and the real-world patient reports clinicians are increasingly hearing in practice.

Do growth hormone secretagogues increase cancer risk?

This episode breaks down the real science behind IGF-1, cancer biology, and compounds like MK-677, Ipamorelin, Sermorelin, CJC-1295, and Tesamorelin.

We review:

This podcast is for informational purposes only and is not medical advice.

Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use my link, I may earn a commission at no additional cost to you.

Support the show: OfflinePeptides Affiliate Link

Does BPC-157 cause cancer — or is that claim being oversimplified?

In this episode of Peptides Explained, we take a study-review approach to one of the biggest concerns surrounding BPC-157: its potential angiogenic effects and whether that could theoretically contribute to cancer proliferation.

Angiogenesis means new blood vessel formation. It is essential for normal wound healing and tissue repair, but it also plays a role in tumor biology. That overlap has led to concerns that BPC-157 could "feed" cancer growth.

But what do the studies actually show?

In this episode, we review key papers on BPC-157, including:

• Hsieh et al., 2017 — VEGFR2 activation and angiogenesis • Radeljak, Seiwerth, and Sikiric, 2004 — melanoma cell-line data • Kang et al., 2018 — cancer cachexia context • Masnec et al., 2015 — corneal injury and neovascularization

We break down the difference between physiologic repair signaling and pathologic tumor angiogenesis, and explain why the current evidence does not support the simple claim that BPC-157 causes cancer proliferation.

That said, the lack of strong human oncology safety data means caution is still appropriate, especially for anyone with active cancer, prior cancer, unexplained symptoms, or elevated cancer risk.

This episode is designed as a literature review for clinicians, physicians, and scientifically curious listeners who want a balanced, evidence-based explanation.

Disclaimer: This content is for informational and educational purposes only and is not medical advice. Always consult a licensed healthcare professional before considering any therapy.

Affiliate disclosure: Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use my link, I may earn a commission at no additional cost to you. https://offlinepeptides.com/ref/JohnGarrett/

#BPC157 #PeptidesExplained #CancerRisk #Angiogenesis #PeptideScience #VEGF #TissueRepair #MedicalEducation #PhysicianReview #Peptides

Tesamorelin is one of the few peptides with FDA approval—but its effects on visceral fat and growth hormone signaling have made it a major topic in metabolic health and body composition circles.

In this episode of Peptides Explained, we break down:

• What tesamorelin actually is • How growth hormone releasing hormone works • Why visceral fat matters metabolically • Clinical trial data and FDA-approved use • Anecdotal outcomes in real-world settings • Risks, limitations, and off-label discussion

We also explain why tesamorelin is different from traditional fat loss medications and why many users report changes in abdominal fat distribution rather than dramatic scale weight loss.

This podcast is for informational purposes only and is not medical advice.

Peptides Explained is an affiliate partner with Offline Peptides. If you use my link, I may earn a commission at no additional cost to you.

In this special update episode, I'm announcing a new affiliate partnership between Peptides Explained and Offline Peptides.

The mission of this podcast remains unchanged: providing clear, responsible, science-based education around peptides, metabolic health, recovery, and emerging therapeutic research.

If you choose to support the show through my affiliate link, I may earn a commission at no additional cost to you.

Affiliate Link: https://offlinepeptides.com/ref/JohnGarrett/

Disclosure: This podcast is for informational and educational purposes only and is not medical advice. Always consult a licensed healthcare professional before considering any therapy or intervention.

Retatrutide may represent the next evolution in metabolic medicine.

In this deep-dive episode of Peptides Explained, we break down the science behind the investigational "triple agonist" peptide that's generating major attention in obesity and metabolic research.

Topics covered: • GLP-1 + GIP + glucagon receptor activation • How retatrutide differs from semaglutide and tirzepatide • Phase 2 clinical trial results • Fat loss vs lean mass loss • Liver fat reduction data • The emerging discussion around obesity-related cancer risk • What may happen after discontinuation • Known side effects and unanswered questions

This episode goes beyond headlines and social media hype to explain the actual biology and human data behind retatrutide.

Peptides Explained is focused on evidence, mechanism, and clarity.

This podcast is for educational purposes only and is not medical advice.

Using the minimal effective dose of GLP-1 medications may be the key to preserving muscle during weight loss. This episode explains how to implement it alongside nutrition and training.

A clinical deep dive into the muscle loss problem on GLP-1 medications. Semaglutide, tirzepatide, and the investigational triple agonist retatrutide all produce remarkable weight loss — but clinical trial data shows that a significant fraction of that loss is lean body mass, not fat. This episode covers the mechanism behind GLP-1-induced muscle wasting, the body composition data from STEP 1 and SURMOUNT trials, who carries the highest risk, and where the next generation of obesity pharmacology — bimagrumab combinations, pemvidutide, and retatrutide's glucagon receptor pathway — is trying to solve the problem. For clinicians, patients, and anyone paying attention to where obesity medicine is actually going.

This podcast is for informational purposes only and is not medical advice.

Breaking news episode. On April 15, 2026, the FDA formally initiated the reclassification process for BPC-157, TB-500, and other peptides restricted since 2023 — publishing a Federal Register notice and scheduling a July 2026 Pharmacy Compounding Advisory Committee meeting. This episode breaks down the full regulatory timeline, what the Category 1 vs Category 2 framework means, what today's action specifically does, and what patients and clinicians should know right now. Clinical, evidence-grounded, no hype.

A clinical breakdown of grey market peptide safety, including contamination risks, testing standards, and how peptide quality impacts biological effects.

GHK-Cu Explained: The Science Behind the Copper Peptide for Skin, Hair, and Healing

A clinical deep dive into BPC-157 covering mechanism, recovery science, dosing patterns, TB-500 synergy, and why it is banned in professional sports.

Are peptides dangerous—or just misunderstood?

In this episode of Peptides Explained, we break down the real science behind peptide safety, how these compounds work in the body, and where risk actually exists.

You'll learn:

• what peptides are and how they function biologically • the difference between FDA-approved, compounded, and research peptides • what changed with peptide regulation and access • how off-label prescribing fits into modern medicine • what recent conversations are getting right—and wrong

This episode focuses on clarity—not hype—so you can understand how peptides fit into real clinical practice.

MOTS-C is one of the most unique peptides being studied today — not because of what it does, but because of where it comes from.

Unlike most peptides, MOTS-C is encoded inside your mitochondria, the part of the cell responsible for energy production. That makes it part of a growing category of mitochondrial signaling peptides that may play a role in metabolism, aging, and cellular energy regulation.

In this episode of Peptides Explained, we break down:

• What MOTS-C is and how it's produced • How it activates AMPK, the body's metabolic "master switch" • Why it's being studied as a potential exercise mimetic • Its effects on insulin sensitivity and glucose metabolism • What the animal research shows vs. the current state of human data • Where it may fit in the broader peptide landscape • Risks, limitations, and why it remains experimental

This episode focuses on the biology and clinical context behind MOTS-C — not the hype.

Disclaimer: This podcast is for informational purposes only and is not medical advice. MOTS-C is not FDA-approved and is currently considered an investigational peptide. Always consult a licensed healthcare professional before considering any therapy.

Peptide science is evolving — and understanding the mechanism is the first step.

Growth hormone peptides are some of the most talked-about compounds in longevity medicine, metabolic health, and hormone optimization. But how do they actually work inside the body?

In this episode of Peptides Explained, we break down the science behind four growth hormone secretagogues: Sermorelin, Tesamorelin, CJC-1295, and Ipamorelin.

Instead of injecting growth hormone directly, these peptides stimulate the pituitary gland to release the body's own growth hormone through different biological pathways.

We explore the physiology of the growth hormone axis, the role of GHRH, IGF-1, and ghrelin signaling, and how these peptides may influence metabolism, recovery, and sleep.

You'll also learn the differences between these compounds, why CJC-1295 and Ipamorelin are often stacked, and what the clinical research actually shows.

Topics covered in this episode include:

• How growth hormone is regulated in the body • The biological role of ghrelin and GH pulses during sleep • The difference between Sermorelin, Tesamorelin, CJC-1295, and Ipamorelin • What DAC (Drug Affinity Complex) means in CJC-1295 • Potential effects on IGF-1, metabolism, and recovery • Possible side effects, including effects on prolactin and glucose metabolism • What the clinical evidence actually supports

As always, this podcast focuses on biological mechanisms and scientific evidence so you can understand how peptide therapies interact with human physiology.

Disclaimer: This episode is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional before considering any therapy.

If you'd like, I can also give you a very effective pinned comment for the YouTube video. That small detail often increases engagement and pushes the algorithm to recommend the episode more.

In Episode 3 of Peptides Explained, we take a closer look at two of the most talked-about peptides in injury recovery circles: BPC-157 and TB-500.

These compounds are often combined in what's popularly called the "Wolverine Stack," a nickname that reflects claims of accelerated healing and recovery. But what are these peptides actually doing in the body, and what does the science really say?

In this episode, we break down the biology behind both compounds, how they interact with tissue repair pathways, and why they've become so popular in athletic and performance communities.

We discuss:

• What BPC-157 is and how it may influence angiogenesis, tendon repair, and tissue healing • What TB-500 (a fragment related to thymosin beta-4) does in terms of cell migration and tissue remodeling • The biological rationale behind combining the two peptides • What the available animal research suggests — and where human clinical data is still lacking • Why these peptides remain in a regulatory gray area • The difference between experimental compounds and FDA-approved peptide therapeutics

The goal of Peptides Explained is clarity, not hype. In each episode we examine the mechanisms, the available data, and the real limitations of what we know today.

Disclaimer: This podcast is for informational purposes only and does not constitute medical advice. Peptides discussed may have different regulatory statuses and should only be used under the guidance of licensed healthcare professionals.

If you're interested in the science behind peptides, injury recovery, metabolism, and emerging therapeutic pathways, this episode will give you a clear, evidence-based overview of one of the most talked-about peptide combinations today.

GLP-1 medications are the most talked-about compounds in modern medicine — and the most misunderstood. Most of the conversation focuses on weight loss results. Almost none of it explains the biology driving those results.

In this episode of Peptides Explained, we break down the science behind three of the most prescribed GLP-1 compounds: semaglutide, tirzepatide, and retatrutide.

Topics covered include:

Whether you're a clinician, a patient, or just someone trying to understand what these medications are actually doing in the body — this episode gives you the mechanistic foundation the headlines leave out.

Disclaimer: This podcast is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional before considering any therapy.

Peptides are everywhere in the health and longevity conversation right now — but most of what's out there skips the fundamentals. Before you can understand semaglutide, BPC-157, or any other compound making headlines, you need to understand what a peptide actually is at the biological level.

In this episode of Peptides Explained, we lay the foundation:

This is the episode to send someone who's heard about peptides but doesn't know where to start. No hype, no bro science — just the biology you need to make sense of everything that comes after.

Disclaimer: This podcast is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional before considering any therapy.